Stryker Co. (SYK) Shares Bought by EP Wealth Advisors LLC

EP Wealth Advisors LLC boosted its stake in shares of Stryker Co. (NYSE:SYK) by 2.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,717 shares of the medical technology company’s stock after purchasing an additional 2,620 shares during the quarter. Stryker comprises 1.6% of EP Wealth Advisors LLC’s holdings, making the stock its 18th largest holding. EP Wealth Advisors LLC’s holdings in Stryker were worth $14,976,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the stock. Truewealth LLC purchased a new stake in Stryker in the fourth quarter valued at about $110,000. Sawyer & Company Inc purchased a new stake in Stryker in the fourth quarter valued at about $125,000. Sit Investment Associates Inc. raised its stake in Stryker by 114.3% in the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after buying an additional 440 shares during the last quarter. Virtue Capital Management LLC purchased a new stake in Stryker in the fourth quarter valued at about $133,000. Finally, San Francisco Sentry Investment Group CA raised its stake in Stryker by 47.8% in the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after buying an additional 325 shares during the last quarter. 75.71% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

In related news, insider David Floyd sold 55,119 shares of Stryker stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $166.58, for a total transaction of $9,181,723.02. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Kevin Lobo sold 39,808 shares of Stryker stock in a transaction that occurred on Thursday, March 22nd. The stock was sold at an average price of $162.90, for a total value of $6,484,723.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 142,489 shares of company stock worth $23,488,485. 7.40% of the stock is currently owned by company insiders.

Shares of NYSE:SYK opened at $155.17 on Friday. The company has a current ratio of 2.29, a quick ratio of 1.59 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $59,504.39, a PE ratio of 23.91, a PEG ratio of 2.28 and a beta of 0.70. Stryker Co. has a 1 year low of $129.82 and a 1 year high of $170.00.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The firm had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the company posted $1.78 earnings per share. The business’s revenue was up 9.9% on a year-over-year basis. research analysts anticipate that Stryker Co. will post 7.12 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a yield of 1.21%. Stryker’s payout ratio is 28.97%.

Several research analysts have recently issued reports on the company. Evercore ISI assumed coverage on Stryker in a research note on Monday, April 2nd. They issued an “in-line” rating and a $165.00 price objective for the company. Needham & Company LLC restated a “hold” rating on shares of Stryker in a research note on Wednesday, January 31st. Raymond James Financial assumed coverage on Stryker in a research note on Thursday, March 15th. They issued an “outperform” rating and a $183.00 price objective for the company. Zacks Investment Research cut Stryker from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $163.00 target price on shares of Stryker in a report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and sixteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $164.77.

ILLEGAL ACTIVITY NOTICE: “Stryker Co. (SYK) Shares Bought by EP Wealth Advisors LLC” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/ep-wealth-advisors-llc-purchases-2620-shares-of-stryker-co-syk.html.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply